The University of Colorado Cancer Center’s new Benign Esophageal and Gastric Multidisciplinary Clinic has its first medical director.
Mark Harden
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Esophageal Cancer Multidisciplinary Clinic
The University of Colorado Cancer Center’s new Benign Esophageal and Gastric Multidisciplinary Clinic has its first medical director.
Cancer Magazine Multidisciplinary Clinic Medical Oncology
A cancer diagnosis is a serious matter – which is why a patient who gets one should seriously consider getting a second opinion.
Colorectal Cancer Multidisciplinary Clinic Clinical
In the earliest days of specialized cancer care, two things often happened: either individual oncologists were burdened with the expectation to know everything, or patients were sent on treatment journeys that could involve multiple visits with multiple clinicians in multiple locations.
As the field of cancer care has grown and evolved, buoyed by tremendous strides in research and therapeutics, patients could increasingly and reasonably hope to live many years, rather than many weeks or months, after a diagnosis. A significant contributor to this hope has been the move toward multidisciplinary care.
Patient Care Community Pancreatic Cancer Multidisciplinary Clinic
Barb Spanjer lay on the floor of her office. She had never been so tired. Her stomach and left side ached, and the pain under her left shoulder blade was relentless. She had seen her doctor a couple of times that autumn of 2017, but the medicine for the ulcer he suspected she had wasn’t working. She had been too tired and too busy running the construction company she and her husband, Steve, owned to follow up with the doctor. But it was getting harder to ignore the symptoms. Something just wasn’t right.
Patient Care Pancreatic Cancer Surgical Oncology Multidisciplinary Clinic
Before receiving a pancreatic cancer diagnosis eight years ago – a diagnosis that resulted from persistent self-advocacy – Carolyn Degrafinried spent one awful weekend wondering if she was losing her mind.
Multidisciplinary Clinic Neuroendocrine
If you drew a line straight back between your eyes, you would hit the pituitary gland in about three inches. Though only about the size of a pea, the pituitary is a master regulator of hormone systems throughout the body. It’s also a fairly common origin of tumors. One in every 10,000 people will be diagnosed with a neuroendocrine tumor originating in the pituitary; one in five people will develop a pituitary mass without knowing it. Most of these pituitary masses aren’t cancer – they become dangerous only when they affect pituitary function or grow large enough to squeeze against other nearby structures, often creating headaches or affecting vision. But some pituitary masses are cancer. Knowing the difference can be tricky and treating these diverse pituitary tumors can be especially challenging.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.